Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A C Vallur

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Cellular and Molecular Life Sciences : CMLS|January 31, 2007
AID in antibody perfectionA C Vallur, M Yabuki, E D Larson, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|November 20, 2014
Specific antibody responses as indicators of treatment efficacy for visceral leishmaniasisA C Vallur, A Hailu, D Mondal, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 19, 2013
Biomarkers for intracellular pathogens: establishing tools as vaccine and therapeutic endpoints for visceral leishmaniasisA C Vallur, M S Duthie, C Reinhart, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Cellular and Molecular Life Sciences : CMLS|January 31, 2007
AID in antibody perfectionA C Vallur, M Yabuki, E D Larson, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|November 20, 2014
Specific antibody responses as indicators of treatment efficacy for visceral leishmaniasisA C Vallur, A Hailu, D Mondal, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 19, 2013
Biomarkers for intracellular pathogens: establishing tools as vaccine and therapeutic endpoints for visceral leishmaniasisA C Vallur, M S Duthie, C Reinhart, et al.
Pageof 1